Robbins Geller Rudman & Dowd LLP announced that investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 have until Monday, August 10, 2026 to seek lead plaintiff appointment in a class action lawsuit alleging securities fraud. The lawsuit claims ADMA Biologics and certain executives made false statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. A Culper Research report on March 24, 2026 alleged that ADMA Biologics' reported growth was driven by channel stuffing and an undisclosed related party distributor, causing the stock to drop over 16%. The following day, ADMA Biologics called the report misleading, but Cantor Fitzgerald downgraded the stock to Neutral from Overweight, leading to a further decline of more than 13%.
ADMA Biologics IncSecurities fraud class action lawsuit alleging false statements and undisclosed related party transaction, channel stuffing, and inadequate internal controls.
